In the GiACTA trial, targeted blockade of IL-6R with TCZ demonstrated superiority to a course of GC alone in achieving steroid-free remission at 1 year, as defined by lack of clinical flare and normal level of IL-6-induced CRP, becoming the first non-steroid FDA-approved treatment for GCA (11). The gene discussed is IL6R; the disease is temporal arteritis.